Company news

Krystal Biotech, Inc. news in 2026

Krystal Biotech, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results

November 2, 2026

Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026

October 22, 2026

Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome

October 15, 2026

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

September 3, 2026

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

August 3, 2026

Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

July 23, 2026

Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600

July 20, 2026

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

May 18, 2026

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

May 7, 2026

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

May 4, 2026

Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

April 21, 2026

VYJUVEK (Krystal Biotech) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

March 13, 2026

Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference

February 23, 2026

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

February 17, 2026

Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

February 10, 2026

Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

February 9, 2026

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

January 10, 2026

Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis

January 7, 2026

Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis

January 7, 2026

Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Calls in 2026

Decks in 2026